Long-term outcomes associated with istradefylline versus catechol-O-methyltransferase inhibitors in patients with Parkinson's disease: a nationwide real-world cohort study
Istradefylline was associated with reduced mortality and treatment escalation but increased fracture risk compared with COMT inhibitors, supporting further evaluation of adenosine A<sub>2A</sub> antagonists.
Authors
- Chengsheng Ju
- Li Wei
- Anette Schrag
- Tsugumichi Sato
- Camille Carroll
- Thomas Foltynie
- Kiyoshi Kubota
- Xi Xiong
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- Tokyo University of Science (JP)
- Food and Drug Safety Center (JP)
- NIHR Newcastle Biomedical Research Centre (GB)
- UCL Biomedical Research Centre (GB)
- University College London (GB)
Publication Details
- Journal
- Parkinsonism & Related Disorders
- Published
- 2026-01-27
- DOI
- https://doi.org/10.1016/j.parkreldis.2026.108211
- Primary Topic
- Adenosine and Purinergic Signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.00